San Diego-dependent Viking Therapeutics marked by itself as a significant competitor during the weight loss drug sector in February immediately after revealing promising details from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the